Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine for Overactive Bladder in Children (FOXY2015)
NCT02614482Phase 3Completed
- Start
- Oct 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fesoterodine in overactive bladder syndrome (OAB). Primary endpoint: Number of Participants with Adverse Events at 12 months. Started Oct 2015; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT02614482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614482.